Current Report Filing (8-k)
June 30 2020 - 8:10AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event
reported): June 29, 2020
RUBIUS THERAPEUTICS, INC.
(Exact name of registrant as specified
in its charter)
Delaware
|
001-38586
|
46-2688109
|
(State or other jurisdiction
of Incorporation)
|
(Commission
File Number)
|
(IRS Employer
Identification Number)
|
399 Binney Street, Suite 300
Cambridge, MA
|
02139
|
(Address of registrant’s principal executive office)
|
(Zip code)
|
(617)
679-9600
(Registrant’s telephone number,
including area code)
N/A
(Former name or former address, if changed
since last report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
¨
|
Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 203.425)
|
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the
Exchange Act (17 CFR 240.14a-12)
|
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b))
|
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
|
|
Trading symbol(s)
|
|
Name of each exchange on which
registered
|
Common Stock, par value $0.001 per share
|
|
RUBY
|
|
The Nasdaq Global Select Market
|
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.
Emerging
growth company x
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 5.02 Departure of Directors or Certain Officers;
Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On
June 30, 2020, Rubius Therapeutics, Inc. (the “Company”) announced that Andrew Oh will step down as the Chief Financial
Officer, effective as of December 31, 2020 (the “Anticipated Separation Date”), or such sooner time as determined
by the Company. In connection with his departure, the Company and Mr. Oh entered into a transitional services and separation
agreement dated as of June 29, 2020 (the “Separation Agreement”).
Consistent with the terms of the Employment Agreement dated
June 29, 2018 between the Company and Mr. Oh, the Separation Agreement provides that Mr. Oh will be entitled to receive, among
other things, the following: (i) salary continuation for nine (9) months following the Anticipated Separation Date and (ii) up
to nine (9) months of continued COBRA coverage for Mr. Oh and his eligible dependents at the Company’s normal rate of contribution
for employees in effect immediately prior to the Separation Date. The Separation Agreement contains confidentiality,
non-disparagement and non-solicitation covenants and a release of claims by Mr. Oh. The foregoing is only a summary description
of the terms of the Separation Agreement, does not purport to be complete and is qualified in its entirety by reference to
the Separation Agreement, which will be filed as an exhibit to the Company’s Quarterly Report on Form 10-Q for the fiscal
quarter ending June 30, 2020.
Item 8.01 Other Events.
On June 30, 2020, the Company issued a press release announcing
the transition of Mr. Oh and providing an update on clinical trial progress for its lead oncology product candidate, RTX-240. A
copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act
of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
Date: June 30, 2020
|
RUBIUS THERAPEUTICS, INC.
|
|
|
|
By:
|
/s/ Pablo J. Cagnoni
|
|
|
Pablo J. Cagnoni
|
|
|
Chief Executive Officer
|
Rubius Therapeutics (NASDAQ:RUBY)
Historical Stock Chart
From Jun 2024 to Jul 2024
Rubius Therapeutics (NASDAQ:RUBY)
Historical Stock Chart
From Jul 2023 to Jul 2024